

<i>Name</i>	<i>Academic Affiliation</i>	<i>COI Disclosures</i>
Lynda G. Balneaves PhD	Department of Psychiatry, University of Toronto	None reported
Venkat Bhat MD	Department of Psychiatry, McGill University	None reported
Pierre Blier MD, PhD, FRCPC	Department of Psychiatry, University of Ottawa	Research grants, personal fees, and/or nonfinancial support from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Forest, Euthymics, Janssen, Lundbeck, Merck, Otsuka, Pfizer, Pierre Fabre, Servier, Shire, Takeda, and Valeant
Daniel Blumberger MD, MSc, FRCPC	Department of Psychiatry, University of Toronto	Research funds/support from Brain Canada, Brain Research and Development Ltd., Brainsway Inc., CAMH Foundation, Campbell Institute, Canadian Institutes of Health Research, National Institutes of Health, Tonika/Magventure, and Invidior
Zafiris J. (Jeff) Daskalakis MD, PhD, FRCPC	Department of Psychiatry, University of Toronto	Honoraria for ad hoc speaking or advising/consulting or received research funds from Brain and Behavior Research Foundation, Brainsway Inc., CAMH Foundation, Campbell Institute, Canadian Institutes of Health Research, Eli Lilly, Hoffmann-La Roche Limited, Merck, Ontario Mental Health Foundation, and Sunovion
Jonathan Downar MD, PhD, FRCPC	Department of Psychiatry, University of Toronto	Research support or honoraria from ANT Neuro, Canadian Institutes of Health Research, Brain Canada, Edgestone Foundation, Klarman Family Foundation, Lundbeck, MagVenture, National Institutes of Health, and Toronto General and Western Hospital Foundation
Murray W. Enns MD, FRCPC	Department of Psychiatry, University of Manitoba	None reported
Guy Faulkner PhD	School of Kinesiology, University of BC	None reported
Benicio N. Frey MD, MSc, PhD, FRCPC	Department of Psychiatry and Behavioural Neurosciences, McMaster University	Honoraria for ad hoc speaking or advising/ consulting or received research funds from Alternative Funding Plan Innovations Award, AstraZeneca, Brain & Behavioral Foundation, Bristol-Myers Squibb, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Daiichi Sankyo, Eli Lilly, Hamilton Health Sciences Foundation, J. P. Bickell Foundation, Lundbeck, Lundbeck International Neuroscience Foundation, Ontario Brain Institute, OMHF, Ontario Ministry of Research and Innovation, NSERC, Pfizer, Servier, Society for Women's Health Research, Sunovion, and the Teresa Cascioli Charitable Foundation

Peter Giacobbe MD, MSc, FRCPC	Department of Psychiatry, University of Toronto	Speaker and consultant honoraria or research funds from Brain & Behavior Research Foundation, Bristol-Myers Squibb, Canadian Institutes of Health Research, Lundbeck, National Institute of Health, and St. Jude Medical
Sophie Grigoriadis MD, PhD, FRCPC	Department of Psychiatry, University of Toronto	Honoraria as a consultant, member of an advisory committee, or for lectures from Actavis, Bristol Myers Squibb, Eli Lilly Canada, and Pfizer, as well as research grant support from Canadian Institutes of Health Research, CR Younger Foundation, Ontario Mental Health Foundation, and Ontario Ministry of Health and Long-Term Care
Mehrul Hasnain MD, FRCPC	Department of Psychiatry, Memorial University of Newfoundland	None reported
Zahinoor Ismail MD, FRCPC	Department of Psychiatry, University of Calgary	Honoraria for ad hoc speaking or advising/consulting or received research funds from Canadian Biomarker Integration Network for Depression, Canadian Consortium for Neurodegeneration and Aging, Canadian Institutes of Health Research, Janssen, Joan and Clifford Hatch Foundation, Kathy Taylor Chair in Vascular Dementia, Lundbeck, National Institute of Aging, Ontario AFP Innovation Fund, Otsuka, Pfizer, and Sunovion
Natalia Jaworska PhD	Department of Psychiatry, McGill University	None reported
Fabrice Jollant MD, PhD	Department of Psychiatry, McGill University	None reported
Sidney H. Kennedy MD, FRCPC	Department of Psychiatry, University of Toronto	Honoraria for ad hoc speaking or advising/consulting or research funds from Allergan, Brain Canada, Bristol-Myers Squibb, Canadian Institutes of Health Research, Janssen, Lundbeck, Ontario Brain Institute, Pfizer, St. Jude Medical, Servier, and Sunovion
Theo Kolivakis MD, FRCPC	Department of Psychiatry, McGill University	Speaker and/or advisory honoraria from Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly Canada, Lundbeck, Lundbeck-Otsuka, Janssen-Ortho, Pfizer, and Sunovion

Raymond W. Lam MD, FRCPC	Department of Psychiatry, University of BC	Honoraria for ad hoc speaking or advising/ consulting or received research funds from Asia-Pacific Economic Cooperation, AstraZeneca, Brain Canada, Bristol-Myers Squibb, Canadian Institutes of Health Research, Canadian Depression Research and Intervention Network, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Coast Capital Savings, Johnson & Johnson, Lundbeck, Lundbeck Institute, Medscape, Pfizer, St. Jude Medical, Takeda, University Health Network Foundation, and Vancouver Coastal Health Research Institute
Anthony J. Levitt MD, FRCPC	Department of Psychiatry, University of Toronto	Research grants, personal fees, and/or nonfinancial support from Eli Lilly, Janssen, Lundbeck, and Sanofi-Aventis
Glenda M. MacQueen MD, PhD, FRCPC	Department of Psychiatry, University of Calgary	Honoraria for advisory board or speaker for Janssen, Lilly, Lundbeck, and Pfizer
Shane J. McInerney MD	Department of Psychiatry, University of Toronto	Fellowship funding from Pfizer
Diane McIntosh MD, FRCPC	Department of Psychiatry, University of BC	Honoraria for ad hoc speaking or advising/consulting or received research funds from Allergan, Bristol-Myers Squibb, Lundbeck, Janssen-Ortho, Otsuka, Pfizer, Shire, and Sunovion
Roger S. McIntyre MD, FRCPC	Department of Psychiatry, University of Toronto	Research grants and/or personal fees and/or nonfinancial support from AstraZeneca, Bristol Myers Squibb, CME Outfitters, Eli Lilly, France Foundation, GlaxoSmithKline, I3CME, Janssen-Ortho, Lundbeck, Merck, National Alliance for Research on Schizophrenia and Depression, National Institutes of Mental Health, Optum Health, Organon, Pfizer, Physicians' Postgraduate Press, Shire, and Stanley Medical Research Institute
Erin E. Michalak PhD	Department of Psychiatry, University of BC	Advisory honoraria from Lundbeck
Roumen V. Milev MD, PhD, FRCPC	Department of Psychiatry, Queen's University	Speaker and consultant honoraria or research funds from Allergan, Bristol-Myers Squibb, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Eli Lilly, Johnson & Johnson, Lallemand, Lundbeck, Merck, Ontario Brain Institute, Ontario Mental Health Foundation, Otsuka, Paladin, Pfizer, Queen's University, Sunovion, Takeda, the University Health Network Foundation, and Valeant
Mandana Modirrousta MD, PhD, FRCPC	Department of Psychiatry, University of Manitoba	None reported

Rachel Morehouse MD, FRCPC	Department of Psychiatry, Dalhousie University	None reported
Daniel J. Müller MD, PhD, FRCPC	Department of Psychiatry, University of Toronto	Research funds from Canadian Institutes of Health Research, Canadian Foundations for Innovation, National Alliance for Research in Schizophrenia and Depression, Ontario Mental Health Foundation, National Institutes of Health, and the University of Toronto
Abigail Ortiz MD, FRCPC	Department of Psychiatry, University of Ottawa	None reported
Sagar V. Parikh MD, FRCPC	Departments of Psychiatry, University of Michigan, Ann Arbor / University of Toronto	Consultant to Bristol Myers Squibb, Lundbeck, and Takeda; has had a research contract with Assurex; and has equity in Mensante
Simon Patry MD, FRCPC	Department of Psychiatry, L'Université Laval	None reported
Barbara Pavlova PhD, RPsych	Department of Psychiatry, Dalhousie University	None reported
Norma Lynn Pearson BSc (Pharm)	Canadian Pharmacists Association	None reported
Lena C. Quilty PhD, CPsych	Department of Psychiatry, University of Toronto	None reported
Arun V. Ravindran MB, PhD, FRCPC	Department of Psychiatry, University of Toronto	Speaker and consultant honoraria or research funds from Bristol-Myers Squibb, Canadian Depression Research and Intervention Network, Canadian Foundation for Innovation and the Ministry of Economic Development and Innovation, Canadian Institutes of Health Research, Grand Challenges Canada, Janssen, Lundbeck, Ontario Mental Health Foundation, Pfizer, and Sunovion
Lakshmi N. Ravindran MD, FRCPC	Department of Psychiatry, University of Toronto	None reported
Paula Ravitz MD, FRCPC	Department of Psychiatry, University of Toronto	None reported
Michael Rosenbluth MD, FRCPC	Department of Psychiatry, University of Toronto	Honoraria from AstraZeneca, Bristol-Myers Squibb, Canadian Psychiatric Association, Eli Lilly, Lundbeck, Otsuka, Pfizer, and Sunovion
Jitender Sareen MD, FRCPC	Department of Psychiatry, University of Manitoba	None reported

Wei-Yi Song MD, FRCPC	Department of Psychiatry, University of BC	Honoraria for ad hoc speaking or advising/consulting or research funds from AstraZeneca, Bristol-Myers Squibb, Canadian Psychiatric Association, Eli Lilly, Forrest Laboratories, Lundbeck, Ortho-Janssen, Pfizer, and Sunovion
Meir Steiner MD, MSc, FRCPC	Department of Psychiatry and Behavioural Neurosciences, McMaster University	None reported
S. Valérie Tourjman MD, FRCPC	Department of Psychiatry, L'Université de Montréal	Honoraria for ad hoc speaking or advising/consulting or received research funds from Bristol-Myers Squibb, Eli Lilly, Janssen, Lundbeck, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Valeant
Rudolf Uher MB, PhD, FRCPC	Department of Psychiatry, Dalhousie University	Research funds from European Commission Framework 6
Ryan J. Van Lieshout MD, PhD, FRCPC	Department of Psychiatry and Behavioural Neurosciences, McMaster University	None reported
Vytas Velyvis PhD, CPsych (Supervised Practice)	CBT Associates of Toronto	None reported
Fidel Vila-Rodriguez MD, FRCPC	Department of Psychiatry, University of BC	Grant funding from Brain Canada and the Canadian Institutes of Health Research
JianLi Wang PhD	Department of Psychiatry, University of Calgary	None reported
Lakshmi N. Yatham MBBS, MBA (Exec), FRCPC	Department of Psychiatry, University of BC	Honoraria for ad hoc speaking or received advising/consulting or research funds from AstraZeneca, Bristol-Myers Squibb, Canadian Institutes of Health Research, Canadian Psychiatric Foundation, Eli Lilly, Forest, GlaxoSmithKline, Johnson & Johnson, National Alliance for Research on Schizophrenia and Depression, Novartis, Pfizer, Abbott, Servier, Stanley Foundation, and Wyeth

With thanks to:

Kimberly Castellano, Sunnybrook Health Sciences Centre

Anna Cyriac, University Health Network

Tricia da Silva, Centre for Addiction and Mental Health

Nicole Edgar, St. Michael's Hospital

Trehani Fonseka, University Health Network

Lindsay Gabel, Centre for Addiction and Mental Health

Paulina Huniewicz

Yena Lee, University Health Network

Victoria Marshe, Centre for Addiction and Mental Health

Marianne McGuire, Providence Care

Cindy Woo, University of British Columbia

Daysi Zentner, Douglas Mental Health University Institute